Johnson & Johnson’s JNJ-N experimental drug helped reduce symptoms of depression as well as insomnia in patients with major depressive disorder (MDD) in a late-stage trial, the company said in a statement on Wednesday. The trial was testing the drug, called seltorexant, in patients with both…#johnsonjohnsonsjnjn #mdd #seltorexant #newjersey #damienconover #globally (Source: Reuters: Health)